Roche’s crovalimab wins FDA approval for paroxysmal nocturnal hemoglobinuria
2024-06-21
JasonDoiy The U.S. has granted approval to Roche (OTCQX:RHHBY)-owned Genentech’s biologic crovalimab to treat the rare condition paroxysmal nocturnal hemoglobinuria. The application was supported by two phase 3 trials, one of which demonstrated that crovalimab achieved disease control and was well-tolerated while the other showed a consistent benefit-risk for theContinue Reading